RESEARCH WEEKLY · VOL. 16
Presented by GEL Labs
Peptide regulation may be approaching another important turning point.
On October 7, The Washington Post reported that the Trump administration is considering an interim enforcement-discretion approach that could temporarily affect how certain unapproved peptides are handled by compounding pharmacies while FDA works through the longer regulatory process. No final FDA rule or official implementation guidance announcing that reported plan had been published as of this issue.
That distinction is important.
There is a major difference between an advisory committee recommendation, a compounded drug, FDA enforcement discretion, and FDA approval.
This week, we’re breaking down exactly where things stand.
HOW DID WE GET HERE?
In July, FDA’s Pharmacy Compounding Advisory Committee, known as PCAC, reviewed seven peptide-related bulk drug substances for possible inclusion on the 503A Bulks List.
The compounds reviewed were:
- BPC-157
- KPV
- TB-500
- MOTS-C
- Semax
- Epitalon
- Emideltide
The committee recommended that the first six be added to the 503A Bulks List and did not recommend emideltide.
View the FDA committee materials
That generated plenty of headlines.
But it did not make those six peptides FDA-approved drugs.
It did not immediately authorize pharmacies to begin compounding them.
And the committee’s vote was advisory rather than binding on FDA. FDA’s advisory committees provide recommendations, while the agency retains decision-making authority.
WHAT IS THE 503A BULKS LIST?
Section 503A of federal law creates a framework under which qualifying licensed pharmacists and physicians may compound certain medications for identified individual patients when statutory conditions are satisfied.
When a pharmacy wants to compound from a bulk drug substance that is not already a component of an FDA-approved drug or covered by an applicable compendial monograph, placement on the 503A Bulks List can become important.
But compounded drugs occupy a different regulatory category from FDA-approved pharmaceuticals.
Compounding permission does not equal drug approval.
FDA-approved drugs go through the agency’s formal premarket review process for safety, effectiveness, manufacturing, labeling, and quality.
A compounded drug generally does not go through that same FDA premarket approval process.
That difference is central to understanding this story.
SO WHAT COULD BE CHANGING NOW?
According to this week’s reporting, officials are considering whether FDA could use interim enforcement discretion for some of the peptides recommended by PCAC while the formal regulatory process continues.
In practical terms, enforcement discretion means FDA may describe circumstances under which it does not intend to take enforcement action even though the permanent regulatory process has not yet been completed.
The reported proposal could include conditions involving things such as adverse-event reporting and patient disclosures. But those details remain subject to change because the reported policy has not yet been finalized publicly by FDA.
Read the October 7 Washington Post report
That makes the wording important:
FDA may be considering an interim pathway.
Not: FDA has approved these peptides.
And not: These peptides are now permanently cleared for compounding.
FOUR DISTINCTIONS WORTH REMEMBERING
1. Advisory Recommendation ≠ FDA Approval
PCAC recommended six peptides for the 503A Bulks List.
That is an advisory regulatory recommendation.
It is not approval of those peptides as drugs.
2. Compounded ≠ FDA-Approved
A licensed pharmacy may, under certain circumstances, prepare compounded medications for individual patients.
That does not make the resulting compounded product an FDA-approved pharmaceutical.
3. Enforcement Discretion ≠ Permanent Regulation
An interim enforcement policy can serve as a temporary bridge while FDA completes rulemaking or evaluates additional information.
It does not necessarily tell us what the final regulation will look like.
4. Research Materials ≠ Pharmacy-Compounding Ingredients
Research-use-only materials exist in a different context from pharmaceutical active ingredients used by licensed compounding pharmacies.
GEL Labs research materials are supplied strictly for laboratory and analytical research and are not pharmacy-compounding products, prescription drugs, or materials intended for human or animal use.
WHAT HAPPENS NEXT?
The next meaningful development would be an official FDA action.
That could take the form of guidance, an enforcement policy, rulemaking activity, changes to the 503A Bulks List, or another formal agency announcement.
The regulatory conversation is moving, but the process is not finished.
That also means headlines claiming that FDA has suddenly “approved” BPC-157, TB-500, MOTS-C, KPV, Semax, or Epitalon would be inaccurate.
None of those substances became an FDA-approved drug simply because PCAC recommended a compounding pathway.
WHY THIS STORY MATTERS
Peptide regulation increasingly sits at the intersection of several very different worlds:
- Laboratory research
- Pharmaceutical development
- Pharmacy compounding
- FDA drug approval
Those categories can sound interchangeable when discussed online.
Legally and scientifically, they are not.
And understanding those differences will become even more important if FDA creates a temporary compounding pathway while longer-term regulations are developed.
THE TAKEAWAY
The biggest development this week isn't that six peptides suddenly became FDA-approved.
They didn't.
The more accurate story is that federal officials are reportedly exploring whether an interim regulatory pathway could exist for some compounded peptide products while longer-term FDA decisions continue.
That would be significant.
But the distinctions still matter:
- Research is not compounding.
- Compounding is not FDA approval.
- Advisory votes are not final agency decisions.
- Enforcement discretion is not necessarily permanent policy.
Those lines may not make the most exciting headline. But understanding them is essential to understanding what is actually changing.
FROM THE GEL LABS RESEARCH DESK
Research Weekly follows peptide science and regulation with an emphasis on separating what has happened from what is being proposed.
This story is moving quickly.
If FDA publishes an official interim policy, final rule, or new 503A guidance affecting these compounds, we’ll break down exactly what changed—and what did not.
RESEARCH REFERENCES
U.S. Food and Drug Administration.
July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting.
FDA committee materials
The Washington Post.
Trump administration paving way for temporary sale of some unapproved peptides.
October 7, 2026.
Read the article
U.S. Food and Drug Administration.
October 29, 2024 Pharmacy Compounding Advisory Committee — Kisspeptin-10.
FDA committee materials
Sobrino V, et al.
Kisspeptins and the neuroendocrine control of reproduction.
Frontiers in Neuroendocrinology. 2022.
PubMed PMID: 34999056
RESEARCH USE ONLY
GEL Labs research products are intended strictly for laboratory and analytical research use only.
Not for human or animal use or consumption. Not a drug, food, cosmetic, compounded medication, or pharmaceutical ingredient.
Regulatory and scientific information in Research Weekly is provided for educational and research-reference purposes only.
0 comments